Amgen's Repatha Data Extends Evidence to Broader High-Risk Population

Amgen, a US-based biotech company, has released new Phase 3 trial results for its drug Repatha (evolocumab) at the European Society of Cardiology Congress 2026. The data shows that Repatha reduces the risk of death in high-risk adults without prior heart attack or stroke.

This finding extends evidence for Repatha to a broader population beyond patients with established cardiovascular events. Amgen highlighted that the data may inform future treatment guidelines and prescribing decisions in cardiovascular risk management.

Repatha is part of Amgen's cardiovascular portfolio, which targets serious chronic diseases. The company has a market cap of about $232.4 billion and is focused on discovering and developing human therapeutics.